The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Liu is a ...

For almost 60 years, scientists have tried to understand why DNA doesn't replicate wildly and uncontrollably every time a ...

Every time a cell divides, it must copy its entire genome so that each daughter cell inherits a complete set of DNA. During ...

The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the ...

STATEN ISLAND, N.Y., Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small ...